Cingulate (NASDAQ:CING) CFO Jennifer Callahan Purchases 4,864 Shares of Stock

Cingulate Inc. (NASDAQ:CING) CFO Jennifer Callahan purchased 4,864 shares of the stock in a transaction dated Friday, February 6th. The shares were purchased at an average price of $5.04 per share, with a total value of $24,514.56. Following the transaction, the chief financial officer directly owned 5,059 shares of the company’s stock, valued at approximately $25,497.36. The trade was a 2,494.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Cingulate Trading Down 5.5%

Shares of NASDAQ:CING opened at $6.82 on Wednesday. The firm’s 50 day moving average is $4.92 and its two-hundred day moving average is $4.30. The firm has a market capitalization of $50.81 million, a P/E ratio of -1.88 and a beta of -0.75. Cingulate Inc. has a 52 week low of $3.20 and a 52 week high of $7.92.

Cingulate (NASDAQ:CING) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.55). Analysts predict that Cingulate Inc. will post -11.69 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CING. Bank of America Corp DE boosted its holdings in shares of Cingulate by 283.1% in the second quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock worth $31,000 after buying an additional 5,543 shares during the period. Soltis Investment Advisors LLC acquired a new stake in shares of Cingulate during the fourth quarter valued at approximately $43,000. XTX Topco Ltd purchased a new stake in shares of Cingulate in the 2nd quarter valued at approximately $45,000. Quantum Private Wealth LLC lifted its position in shares of Cingulate by 140.0% in the 3rd quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company’s stock valued at $94,000 after acquiring an additional 14,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Cingulate by 43.9% in the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock worth $265,000 after purchasing an additional 18,629 shares during the period. Institutional investors own 41.31% of the company’s stock.

Cingulate News Summary

Here are the key news stories impacting Cingulate this week:

• Positive Sentiment: CEO Shane J. Schaffer bought 6,809 shares at an average price of ~$5.04, raising his stake >200% — a clear insider vote of confidence. Cingulate CEO Shane Schaffer Purchases 6,809 Shares
• Positive Sentiment: CFO Jennifer L. Callahan purchased 4,864 shares (~$5.04), increasing her holding materially — reinforces the management accumulation theme. CFO SEC Filing
• Positive Sentiment: EVP Matthew Brams acquired 1,946 shares at ~$5.04, a meaningful increase in his stake. EVP SEC Filing
• Positive Sentiment: Director Peter J. Werth bought 19,455 shares at ~$5.04 (≈$98k), materially increasing his position — adds institutional‑style endorsement from the board. Director SEC Filing
• Neutral Sentiment: A MedicalXpress article reports impaired brain energy metabolism in people with post‑COVID — relevant scientifically but only indirectly material to Cingulate unless tied to the company’s programs. Study shows impaired energy metabolism in the brains of people with post-COVID
• Neutral Sentiment: Short‑interest reporting shows an apparent “0 shares” figure on Feb. 10 (likely a reporting glitch), creating temporary data uncertainty for traders; treat this datapoint cautiously.
• Negative Sentiment: Earlier (Jan. 30) short interest rose to ~389,923 shares (~5.5% of float) with a short‑ratio near 1 day — active short selling that can amplify downside and cap rallies if selling intensifies.

Analysts Set New Price Targets

CING has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Cingulate in a research note on Wednesday, January 21st. Ascendiant Capital Markets lowered their target price on shares of Cingulate from $62.00 to $58.00 and set a “buy” rating on the stock in a research note on Monday, December 8th. Finally, Roth Mkm dropped their price target on shares of Cingulate from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.33.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.